Earnings call
Advanced Enzyme Technologies Q2 FY26 earnings call
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
Specialized Manufacturing business expects margins of about 8% to 10% in this particular company, and will go with the same kind of margin as last year. The company reported revenue of INR 1,845 million in the quarter ended September 30, 2025, up 26% YoY and down 1% compared to the previous quarter. Human Healthcare segment contributed 66% of total revenues.
The numbers management gave
Results
- The company reported revenue of INR 1,845 million in the quarter ended September 30, 2025, up 26% YoY and down 1% compared to the previous quarter.
Show source
Our top line for the quarter stood at INR 1,845 million, reflecting a 26% YoY growth and marginally decreased by 1% compared to the previous quarter.
- The company reported EBITDA of INR 601 million in the quarter ended September 30, 2025, up 42% YoY and 6% QoQ.
Show source
EBITDA came in at INR 601 million, which is a 42% increase YoY and 6% higher QoQ.
- EBITDA margin was 33% in the quarter ended September 30, 2025.
Show source
Our EBITDA margin for the quarter stood at 33%.
- The company reported profit after tax of INR 447 million in the quarter ended September 30, 2025, up 34% YoY and 11% QoQ; PAT margin was 24%.
Show source
Moving to profitability, our profit after tax reached INR 447 million, registering a 34% growth YoY and 11% increase QoQ.
- Animal Healthcare segment recorded revenue of INR 193 million, up 6% YoY and down 26% QoQ, and accounted for 10% of total revenues in Q2 FY26.
Show source
Page 2 of 22 Next, we have Animal Healthcare, revenues rose to INR 193 million, delivering a 6% increase YoY and 26% decline QoQ.
- Bioprocessing segment recorded revenue of INR 255 million in the quarter ended September 30, 2025, up 52% YoY and 8% sequentially, primarily on account of robust food business performance.
Show source
Turning to Bioprocessing, t his segment recorded strong growth of 52% during the quarter, reaching INR 255 million and 8% sequential growth.
Show 23 more statements
Results
- Food business grew 77% YoY and 18% QoQ in the quarter ended September 30, 2025.
Show source
The food business grew by 77% on YoY basis and 18% on QoQ basis.
- Non-Food business declined 4% YoY and 20% QoQ in the quarter ended September 30, 2025.
Show source
It de-grew by 4% on YoY basis and 20% on QoQ basis.
- Specialized Manufacturing segment recorded revenue of INR 185 million, up 54% YoY and 30% sequentially in the quarter ended September 30, 2025, representing 10% of overall revenue.
Show source
Lastly, the Specialized Manufacturing segment delivered a strong growth of 54% on YoY basis and 30% on sequential basis, reaching INR 185 million.
- Consolidated R&D spend was INR 84 million during Q2, about 5%, compared with 6% in Q2 of FY25, without considering intercompany elimination; consolidated R&D spend was about 3% during Q2 and 5% in Q2 of FY25.
Show source
On consolidated basis, R&D spend is about 5%, INR 84 million during Q2 and 6% in Q2 of FY25.
- The company derived 50% of total revenue from India on a six-month basis in YTD FY26.
Show source
So total revenue, 50% has come from India on six-month basis, YTD FY26.
- The company derived 30% of revenue from the Americas on a six-month basis and recorded a 4% decline in its numbers compared with the previous year's six months.
Show source
The 30% has come from Americas where we see a decline of 4% in our numbers as compared to last year's six months.
- The company derived about 6% of revenue from Europe and recorded 51% growth from this geography in the six months of the current year.
Show source
Europe is about 6% of our revenue, and we have seen 51% of growth from this geography.
- The company derived about 12% of revenue from Asia and recorded 4% growth in this geography in the six months of the current year.
Show source
Asia is about 12% of our revenue coming from there in the six months of current year, and we have seen 4% of growth in this particular geography.
- The company derived about 2% of revenue from the rest of the world and recorded a 30% increase in the six-month period.
Show source
The rest of the world, which constitute about 2% of our revenue, and 30% increase in six months period.
- Largest product sales were INR 829 million for the six months, compared with INR 555 million for the previous-year six months.
Show source
Beni Rauka: Yeah, Lakshmi Narayan ji, INR 829 million as compared to INR 555 million.
- Overall impact on EBITDA is INR 10 crore to INR 11 crore and on PAT is INR 7 crore to INR 8 crore.
Show source
Beni Rauka: So, INR 10 crore to INR 11 crore is impact on EBITDA and INR 7 crore to INR 8 crore on PAT on overall basis.
- Advanced Enzyme Technologies' food segment revenue was about INR 380 million for six months, compared with INR 312 million in last year's six months.
Show source
So for six months, it is about INR 380 million as compared to INR 312 million.
- Advanced Enzyme Technologies' animal feed business revenue was INR 453 million for six months, compared with INR 353 million in last year's six months.
Show source
And other than that, the animal health, the animal feed business, that is what we call it, is INR 453 million as compared to INR 353 million in last year's six months.
- Advanced Enzyme Technologies' bio-catalysis total for six months was about INR 128 million, compared with INR 104 million last year.
Show source
Beni Rauka: So, I think bio-catalysis total for six months stood about, INR 128 million as compared to INR 104 million last year.
- Advanced Enzyme Technologies' human nutrition segment grew about 21% in the half year ended September 30, 2025, with growth attributed to good orders for many products and a different product mix.
Show source
In human nutrition, we are getting a good growth of about 21%.
- Advanced Enzyme Technologies' animal health segment's 28% growth in the half year ended September 30, 2025 came from India and international markets, mainly following work over the last three, four years and increased customer orders.
Show source
In animal health segment, again, we are getting 28% of growth.
- Advanced Enzyme Technologies' bioprocessing food business grew 22% in the half year ended September 30, 2025.
Show source
And bioprocessing food is another area where we see the good growth of 22%.
- Advanced Enzyme Technologies' combined growth across the businesses discussed was 23% in the half year ended September 30, 2025.
Show source
So, all put together is given a kind of growth of 23%.
- Advanced Enzyme Technologies' US sales were down by 7%, 8%, whatever that number is, and the slowdown was already affecting the company to some level.
Show source
Mukund Kabra: So, this is already affected, if you really look at it, our US sales is down by 7%, 8%, whatever that number is.
- Advanced Enzyme Technologies' R&D expenses were about INR 19 crore or so in the quarter ended September 30, 2025.
Show source
Beni Rauka: I think an absolute number, we have about, INR 19 crore or so.
- Advanced Enzyme Technologies' four segments were all doing well in the two quarters, with growth reflecting past efforts and support and numbers from different customers, rather than one particular cause.
Show source
So, all these segments are doing well in these two quarters, and there are several things because the efforts have gone in the past, and now you are getting those kinds of numbers from different customers.
- Human Healthcare segment recorded revenue of INR 1,212 million in Q2 FY26, up 22% YoY and down 1% QoQ, driven by higher Pharma/API and Nutritional sales across domestic and international markets. Replaced by a later filing.
Money and capital
- The company is targeting to capitalize some of the assets by the end of March.
Show source
Probably, by the end of the March, it should have some kind of shape should come up, and, probably, we are targeting to capitalize some of the assets during that time.
What it expects ahead
What management expects
- Specialized Manufacturing business expects margins of about 8% to 10% in this particular company, and will go with the same kind of margin as last year.
Show source
In this particular company, I think, maybe, about 8% to 10% of the kind of the margins we are going to have.
- The company expects to maintain PAT margin of about 21% to 22% and EBITDA margin of 30% to 32%, except for the impact of the tariff.
Show source
Otherwise, I think we will continue to have the margin of PAT about 21% to 22%, EBITDA of 30% to 32%.
- The company expects its B2B business to reach somewhere around INR 1 CR to INR 1.5 CR this year, lower than initially budgeted.
Show source
This year, probably, we'll be hitting somewhere around INR 1 CR to INR 1.5 CR, which is lower than what we budgeted initially.
- The company had anticipated 9%, 10% of growth in its US business this year, but the slowdown had already affected it.
Show source
If we really go back and when we were calculating, we were anticipating some 9%, 10% of growth in the US business this year, but this has already affected us.
- The company will have mid-double digit growth this year, maintaining its initial guidance, amid uncertainties around the world.
Show source
What I would say is that we will still stick with the numbers and the initial guidance what we have given that we will have this year, like, a mid-double digit growth.
- The company anticipates that its strong growth trajectory will continue across all business segments in the foreseeable future. Replaced by a later filing.
Show source
We anticipate that our strong growth trajectory will continue across all business segments in the foreseeable future.
What it is building and selling
Demand and pricing
- Specialized Manufacturing business has low margins, with depreciation expenses having gone up as expansion and capacity utilization increase; the domestic market is more competitive in obtaining margins.
Show source
And particularly, when you have, the geography-wise, if you look at the numbers, then I think the domestic market little bit more competitive in the sense in getting the kind of the margins.
Segments
- Human Healthcare segment contributed 66% of total revenues.
Show source
Human Healthcare remains the vital of our port- folio, contributing 66% of our total revenues.
- Business segments include nutraceutical, which comprises pharma and Nutra; bioprocessing, which comprises food and non-food; and animal feed.
Show source
Second one is bioprocessing business where food and non-food business is a part of it, and the third one is animal feed business.
- Growth comes from existing products as well as new products, and new products and launches are in the pipeline, although not all products scale up quickly.
Show source
We heavily work from the R&Ds, and the new products and new launches are always into the pipelines.
Risks, rules and outside factors
Outside factors
- The company would have a 2% impact on EBITDA at worst case if it absorbs everything going forward, in relation to US tariffs at 50%.
Show source
Mukund Kabra: As like last time also, like, I think, like, we mentioned that at the worst case, we will have a 2% impact on the EBITDA if we absorb everything going forward as well.
Everything else said on the call
Group structure
- The company will transfer its B2B business from Advanced Enzyme to the new company it recently formed.
Show source
So, we will be transferring that business.
- The new company will partially become active by the end of this fiscal year.
Show source
It will partially become active by the end of this fiscal year.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Rachna K: Similarly, for our product categories, animal healthcare, human healthcare, food processing and specialized manufacturing. And what were the growth drivers? If you could give some color on each category separately? And what caused a decline in industrial processing revenues to remain for that? And do we see the growth trajectory sustaining over the long term? These would be my questions.
Answer, mukund kabra
Mukund Kabra: So, good evening, Rachna Ji. I would say this way, when we talk about India, Europe, all the different names, numbers can be given by Rauka Ji. But in general, it's, marketing we're putting up from last so many days into the different areas, different geographies, Asia, as well as Europe. And all of this, it's a long-term, like, efforts. You cannot just, go and say that in one day, go , come and can go. So, I would put it this way. It's into the all the different segments which we are working.
Answer, mukund kabra
Page 4 of 22 In Europe, we were working into the baking areas . We were working into those different food areas. In India as well, we are working on a different food areas. In other market, Asian markets, we are working into the different pharma areas. And all of those, give you some effect. At the same time, we did have, some back footing because of the tariff issues, which is there. And what we anticipated, little more growth because of tariff issues, which are still there, and we anticipate that may continue.
Answer, mukund kabra
We don't know when it will be because the uncertainty is there. And, probably, that is the one area which has caused a little bit lower sales in the US as of now. And also, in some of the areas where the indirect market is there. So, we are waiting how this tariff issues pan out to make further strategies, what we should do, what we shouldn't do. But what I would like to say that it's like long-term efforts, which are turning into the some sort of growth.
Answer, beni rauka
Beni Rauka: Yeah. I would like to give you the numbers. So total revenue, 50% has come from India on six-month basis, YTD FY26. The 30% has come from Americas where we see a decline of 4% in our numbers as compared to last year's six months. Europe is about 6% of our revenue, and we have seen 51% of growth from this geography. Asia is about 12% of our revenue coming from there in the six months of current year, and we have seen 4% of growth in this particular geography. The rest of the world, which constitute about 2% of our revenue, and 30% increase in six months period.
Question
Rachna K: Yeah. The drivers of growth because the growth rates this quarter are very good. So, just wanted an idea on those aspects.
Answer, mukund kabra
Mukund Kabra: It's all the different areas and different products, every everything is showing growth. If you really look at it, our anti-inflammatory product growth is also there. Our baking enzyme's growth are also there. Animal feed enzymes also there. So, all of them are growing at this point of time. There are a lot of research which is happening. Those are also supporting into some of the areas, and those are also going to support in the future.
Question
Rachna K: Okay. Thank you. And one more question. How will we offset the impact of tariffs? You said we have some strategies in place. So, if you could provide some color on that as well.
Answer, mukund kabra
Mukund Kabra: Rachna Ji, I don't want to reveal those strategies. We will wait and see how the things pan out, and then we will take appropriate call at a given time. How do we need to do? We are still working on different area. If this persists, then what we need to do? Page 5 of 22 Rachna K: And how do you think the growth in H2 FY26 will pan out?
Question
If you could provide some color on that as well.
Answer, mukund kabra
Mukund Kabra: There are a lot of uncertainties out there. What I would say is that we will still stick with the numbers and the initial guidance what we have given that we will have this year, like, a mid-double digit growth. And I would like to continue with that as of now, and we'll see how the things pan out in the given time because I see a lot of uncertainties around the world. So, I don't want to comment too many things as of now.
Question
Umang Shah: Okay. Sure. Hi, sir. Congratulations on good set of numbers, and thank you for the opportunity. Sir, I have two questions. First one, the specialized manufacturing business. Right? Last two years, the bottom line is around INR 4 crores or so in that subsidiary. At what scale do you think the margins will scale up? And what is the current line? And where do you think the margins will land at for next two years?
Answer, beni rauka
Beni Rauka: I mean, see, margin in that particular business is really low. And currently a lot of expansion is happening. So I think, the depreciation expenses have gone up and capacity utilization has also gone up. But yet, the margin is low in that particular segment. And particularly, when you have, the geography-wise, if you look at the numbers, then I think the domestic market little bit more competitive in the sense in getting the kind of the margins. So, I think we will go with the same kind of margin that is what we had in the last year. In this particular company, I think, maybe, about 8% to 10% of the kind of the margins we are going to have.
Question
Umang Shah: Okay. Sure, sir. Very helpful, sir. Sir, and how is the competitive intensity for serratiopeptidase in India?
Answer, mukund kabra
Mukund Kabra: Competition is always there, Umang Ji, and it will continue. Page 6 of 22 Umang Shah: Right.
Question
No. Because last year, the competition had significantly increased after many years. So, do we continue with that intense com- petition or now you see that the rates are still forming up?
Answer, mukund kabra
Mukund Kabra: No. I would say that rates are more or less stable. And competition is going to be there, and then you need to deal with the competition with whatever the tools which you have.
Question
Umang Shah: Right, sir. And, sir, in the last call, you had helpfully mentioned the total impact on our profits for the full year if the US tariffs go to 50%. Now, they are at 50%. So, do we work with those numbers? And right now, what are the conversations like with our customers? Are they taking some impact of the tariffs?
Answer, mukund kabra
Mukund Kabra: As like last time also, like, I think, like, we mentioned that at the worst case, we will have a 2% impact on the EBITDA if we absorb everything going forward as well.
Answer, mukund kabra
Mukund Kabra: The way we will work it out is some of them probably will absorb. Some of them will try to pass it on. It depends on the customer. It depends on the strategies. It also depends on the volume of the customer, size of the customers, and what different actions which we need to take. But still, it's absorbable if the volume goes up. So, we are open on that as of now, and we'll see how it works out.
Question
Thank you for the opportunity. I'm fairly new to the company. If you don't mind, can you please explain me the business vertical? And my second question is, what are the key growth drivers for your double-digit growth for the year? As in, are you planning to launch more product or are you planning to scale the existing products?
Answer, mukund kabra
Mukund Kabra: So, Raman Ji, the business segments what we have and we have mentioned on our presentation on the website as well, but I will just for your information, I will give you in short. So, we do have our nutraceutical business where, like, all the pharma and Nutra business is a part of it. Second one is bioprocessing business where food and non-food business is a part of it, and the third one is animal feed business. And I would like to say that the growth is always with the existing products as well as the new products. We are more R&D-driven company. We heavily work from the R&Ds, and the new products and new launches are always into the pipelines. But all the products don't scale up that fast or that quickly.
Answer, mukund kabra
There is always some time lag in our area. And we intend to increase our R&D intensity as well going forward. We are coming up with the new R&D center as well where we would increase our R&D capacity multifold than what we have at present. So, the simple answer is it's a combination of both existing products as well as the new products what we are going to launch. Some of them not maybe like individual form, maybe in the blends and formulation form.
Question
Raman KV: Understood, sir. Sir, while looking at the historical figures, I have noticed that our historical margin before COVID, it was around 44% to 46%. Can we assume this 30% to 32% kind of margin is the new normal? Or can we go back to the 44% margin?
Answer, mukund kabra
Mukund Kabra: Since the last few calls also, we are saying that at this point of time, our view is this is going to be the new normal for us. If it improves, it is good, but we will go with these numbers as of now.
Show 21 more questions
Question
Raman KV: Okay, sir. And so my last question, it's more of a doubt. If you can give ballpark figures, which is a better margin business amongst all the vertical?
Answer, mukund kabra
Mukund Kabra: It's we don't really track with the different products, different margins, different areas to that level. But I would say that all of the segments are more or less equal. But whenever there is a sale from our US subsidiary, it adds up to the margins.
Question
I just want to understand our largest product sales. What has been the sales for the last six months versus the previous-year six months?
Answer, beni rauka
Beni Rauka: Yeah, Lakshmi Narayan ji, INR 829 million as compared to INR 555 million.
Question
Lakshmi Narayan: Okay. And if you look at it, what is our India market? This is entirely domestic, I believe. Right? Now in this, what is the total market size for this product?
Answer, mukund kabra
Mukund Kabra: It's difficult, Lakshmi Narayan Ji. But I would say that we command maximum percentage of it.
Question
Lakshmi Narayan: Okay. I mean, when you say, is it another 35% or 20% more would be that? I mean, I just want to understand what is the broad number? What is the range it should be?
Answer, mukund kabra
Mukund Kabra: See, the application can be different. It can be into the other areas as well. You can extend the applications. Right? So, it's very difficult to put it into the actual number. So, that's a challenge Lakshmi Narayan Ji to tell you exact number.
Question
Lakshmi Narayan: Got it. Now, how many players are there right now? Because the market itself is around INR 200 crores or so, I mean, then it's a different thing as well as when the market is large. So, because it needs a minimum order, minimum size for somebody to set up this particular product. Correct? Now in your view, what is the minimum revenue somebody has to generate to actually enter into this particular business?
Answer, mukund kabra
Mukund Kabra: I would put it this way, individual single product, probably, it's very difficult to survive. You need to have different batteries of the products. You need to have different products. You need to take the capacity utilization very differently. Because just giving the one product doesn't work out.
Question
Lakshmi Narayan: Got it. Thanks. Sir, and we talked about the American business and there has been tariff impact. Now, is it that the entire product that are being shipped to the US suffers from this tariff? Can you just tell me what is the percentage? Because there is if you add value, then the tariff becomes different, right? So, what is the weighted average thing for this? And then how do you -- what kind of mitigation you can actually do? I know you talked about some of the things like 2% is an impact. Just want to understand how much would get suffered with this tariff? And then what is the weighted average? And then what are your mitigations?
Answer, mukund kabra
Mukund Kabra: If I go with the last year's number, at the worst scenario, probably, like, we'll have impact of INR 7 crores, INR 8 crores. Page 9 of 22 Lakshmi Narayan: Okay.
Question
In the EBITDA?
Answer, mukund kabra
Mukund Kabra: Yeah. I mean, like, total whatever we can call PAT, EBITDA or Gross margin.
Question
Lakshmi Narayan: Sorry, sir. I didn't get a clear end.
Answer, beni rauka
Beni Rauka: So, INR 10 crore to INR 11 crore is impact on EBITDA and INR 7 crore to INR 8 crore on PAT on overall basis.
Question
Lakshmi Narayan: And how do you intend to mitigate it? Is there a way that you can mitigate by changing the source of origination or keeping the place at which the value is being added. Is there something which you can mitigate?
Answer, mukund kabra
Mukund Kabra: We'll explore all of those areas.
Question
Lakshmi Narayan: Sir, and if you look at India, non-pharma business. Right? So can you just give me a bit of India non-pharma and how it has actually grown?
Answer, mukund kabra
Mukund Kabra: So, when we talk about India, non -pharma, it is basically textile and leather, and we mentioned many times that that is not our focus area, Lakshmi Narayan Ji, but we intend to be there and see how is the market moving. Maybe, like, in the future, we will like to come out with the products into those areas.
Question
Lakshmi Narayan: Yeah. Because I thought there is a sizable amount of animal feed business.
Answer, mukund kabra
Mukund Kabra: Animal feed doesn't come into the non-food areas. The non-food areas basically comprises of textiles and leather.
Question
Lakshmi Narayan: I talked about -- I was looking for non-pharma, sir. Sorry. I think I wanted to know the non-pharma part of India. What is the revenue that is actually for the last six months and how it has grown, okay, excluding pharma domestic sales? Page 10 of 22 Mukund Kabra: Rauka Ji can give the numbers of the food business, how it has grown, and basically, the other one is the an imal feed.
Answer, mukund kabra
Overall numbers, we don't have numbers, like, separately, geography-wise or others. Right? So, you can give the six-month comparison, Rauka Ji. Beni Rauka: Okay. So, I'm just giving you a number for food segment. So for six months, it is about INR 380 million as compared to INR 312 million. And other than that, the animal health, the animal feed business, that is what we call it, is INR 453 million as compared to INR 353 million in last year's six months.
Question
Lakshmi Narayan: Okay. So, then moving on to Europe, which has also grown for us, can you just give me a bit of what is growing in the Europe?
Answer, mukund kabra
Mukund Kabra: No. I would put it, like, say, Lakshmi Narayan Ji, we shouldn't go on a QoQ or half yearly basis. Overall yearly basis, it has more relevance. I would say that the focus area is still the same. What we have into the food areas and particularly into some of the nutraceu- tical areas, which is still there into the Europe, we are registering our few products in the EFSA, and we are waiting for the novel food approval. If that works out, then probably, the Europe business can grow much faster. Similarly, we are waiting for some of the approva ls for some of the pharma areas into the Asian areas. If those happens, probably, that should, really increase the growth into those areas as well, particularly.
Answer, mukund kabra
It's a long, time-consuming process. The process we started one and a half years back, and still we are waiting. Maybe like six months to eight months down the line, we expect that, that should materialize.
Question
Lakshmi Narayan: Sir, one just last question. The American business has shown a little slower growth. So, is it completely related to tariffs? Or it is something outside the tariff issue that is actually leading to this?
Answer, mukund kabra
Mukund Kabra: We don't know at this point of time, Lakshmi Narayan: Ji, but what we can say that into the last particularly last two, three months, there is a lot of slowness what we have observed.
Question
Nitish Rege: Hi. Thank you for the opportunity. Hope, I'm audible. Just a question on the guidance which you said you want to maintain at the mid- teens level. So, you expect to which our revenue growth rate to decline? We've done 23% YoY in the first half. So, if you can do mid-teens, we expect to which to be a slower growth for us?
Answer, beni rauka
Beni Rauka: I think, that's what we have been telling because of a lot of uncertainties around the world. We feel like, we need to have the same guidance for the time being.
Question
Nitish Rege: Got it. And just if you could share some color on margins, do you expect it to be at this 32.5% EBITDA margin levels going at?
Answer, mukund kabra
Mukund Kabra: Margins. Beni Rauka: The margin, I think, we already mentioned, except, like, the impact of the tariff. Otherwise, I think we will continue to have the margin of PAT about 21% to 22%, EBITDA of 30% to 32%. That's what we are still managing.
Question
Nitish Rege: Can you quantify the number?
Answer, beni rauka
Beni Rauka: So, I think bio-catalysis total for six months stood about, INR 128 million as compared to INR 104 million last year.
Question
Zakinaher Nasser: Thank you, sir. Best wishes.
Answer, mukund kabra
Mukund Kabra: So we are, like, main B2B company, and that is where, we are separating that arm from Advanced Enzymes to the new company what we just recently formed. So, we will be transferring that business. As of now, like, we do have a good growth on a smaller number. This year, probably, we'll be hitting somewhere around INR 1 CR to INR 1.5 CR, which is lower than what we budgeted initially. But we'll see. And there is a young dynamic team which is working behind it, and it's a different company. That's what we are try ing to aim at it to develop it further.
Answer, mukund kabra
And I have to put it this way. Probably, by the end of the March, it should have some kind of shape should come up, and, probably, we are targeting to capitalize some of the assets during that time. It will partially become active by the end of this fiscal year. Shreyans Gathani By March? Okay. Got it. And last is, the European subsidiary, we had an order, like, any kind of similar orders we're looking at?
Question
Aditya Khandelwal: Yeah. Hi, sir. Thanks for the opportunity. Sir, this question has been asked before, but I'll also try my luck. So, see, the growth which we have witnessed in the first half, more than 20%. So, if you could just provide some flavor of what is leading to such high growth? So, is it that we have one new customer or some of our products have clicked, which is leading to the high growth? Or is it just purely a base effect playing out? So if you could just spend some time and help us understand what is leading to this high growth?
Answer, beni rauka
Beni Rauka: So, we are getting good growth in all four segments. In human nutrition, we are getting a good growth of about 21%. This is our largest business. And here, we have different products and different product mix. So, many of, products are getting good orders. And because of that, I think the growth is good in this particular segment. In animal health segment, again, we are getting 28% of growth.
Answer, beni rauka
So, that is coming from India as well as from the international market. And this is because, mainly, we have done a lot of work in last three, four years. So, I think we are getting now a lot of orders from our customers. And bioprocessing food is another area where we see the good growth of 22%. So, all these segments are doing well in these two quarters, and there are several things because the efforts have gone in the past, and now you are getting those kinds of numbers from different customers. So, it's not only one particular thing which we can say, okay, it's only because of A, B, C, D, reason. There are several things which has gone back into getting this kind of support and numbers.
Answer, beni rauka
Page 17 of 22 We will look at the contract manufacturing business, I mean, there, we have effervescent based technology, and we could see 42% of growth in this particular business as well, which is run by our subsidiary company. So, all put together is given a kind of growth of 23%.
Question
Abhishek Kohli: Okay. And my question three. This is my final question. I remember, like, our CFO mentioning that there was a reduction in the number of inquiries. Despite that, you are guiding for mid-teens growth. Like, my main question is, will this reduction in inquiries be affecting the H2 or next fiscal year, '27?
Answer, mukund kabra
Mukund Kabra: So, this is already affected, if you really look at it, our US sales is down by 7%, 8%, whatever that number is. So, it's already affecting us to some level because we feel some of the slowness. If we really go back and when we were calculating, we were anticipating some 9%, 10% of growth in the US business this year, but this has already affected us.
Question
Got it, sir. And just last one thing, R&D expenses, is it simply a function of higher sales due to which they have declined or has it also ramped down?
Answer, beni rauka
Beni Rauka: I think an absolute number, we have about, INR 19 crore or so.
Questions about this call
- When was the Advanced Enzyme Technologies Q2 FY26 earnings call transcript filed?
- Advanced Enzyme Technologies filed the transcript with the exchange on 17 Nov 2025. This page is built from that transcript.
- What does this page list?
- 42 statements from the transcript across 7 topics, 33 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 31 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.